Using genetic profiling to improve cancer treatment
Official title: Mutational Oncology in Clinical Practice: Development of a Comprehensive Cancer Genome Profile Pathway.
Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06020625 · Data updated 2026-11-12
This study is testing if using genetic information can help doctors choose better treatments for cancer patients based on their specific tumor characteristics.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Rome) |
| Status | Recruiting |
| Started | January 1, 2022 |
| Main results expected | May 1, 2023 |
| Study ends | January 2032 |
| Registry record updated | August 31, 2023 |
| Trial ID | NCT06020625 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with advanced or metastatic cancers such as lung, breast, ovarian, pancreatic, prostate, colorectal, melanoma, GIST, thyroid, endometrial, and cholangiocarcinoma.
✕Probably not a fit
Patients with early-stage cancers or those not meeting the specific cancer types outlined in the eligibility criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the integration of molecular characterization into clinical practice to enhance the diagnosis and treatment of various cancers. By utilizing next-generation sequencing (NGS), the study aims to analyze a large number of samples simultaneously, generating extensive genomic data that can identify oncogenic drivers and gene alterations. These insights are crucial for predicting patient responses to new molecularly targeted therapies, particularly for patients with specific types of neoplasms. The research is conducted at Policlinico A. Gemelli, which has been recognized for its commitment to personalized medicine and innovative biotechnology.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized cancer treatments for patients based on their genetic profiles.
How similar studies have gone: Other studies utilizing genetic profiling and NGS have shown promising results in improving treatment outcomes for cancer patients, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
\- Patients with neoplasm of the lung, breast, ovary, pancreas, prostate, colorectum, melanoma, GIST, thyroid neoplasm, endometrium, and cholangiocarcinoma: 1. BREAST Locally advanced or metastatic, hormone-responsive, HER2-negative breast neoplasm, progressing after endocrine therapy. 2. LUNG Metastatic disease. 3. OVARY Any stage of nonmucinous, non-borderline epithelial carcinoma of the ovary, fallopian tube, or primary peritoneal carcinoma. 4. PANCREAS Metastatic disease. 5. PROSTATE Metastatic castration-resistant disease. 6. COLORECTUM Metastatic disease. 7. MELANOMA Stage IV or stage III undergoing surgery. 8. GIST Profiling of c-KIT in case of metastatic disease or for patients undergoing surgery and of PDGFRα for all patients with inoperable or metastatic disease. 9. THYROID 10. ENDOMETRIUM 11. CHOLANGIOCARCINOMA
Where it's running
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy Recruiting
Study contacts
- Study coordinator: Giovanni Scambia
- Email: giovanni.scambia@policlinicogemelli.it
- Phone: 0630158668
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sirolimus for ApoE4 Carriers: Testing Brain Blood Flow in Women 45-65
Researchers will test whether sirolimus can improve brain blood flow in healthy ApoE4-positive women ages 45 to 65 compared with a placebo.
-
Germline testing for inherited risk of myeloid blood cancers
This research will test whether a germline genetic test (MyeloGen Gene Panel) can find inherited changes linked to myeloid blood cancers in adults who have been diagnosed.
-
Examining the role of vaginal microbiome in ovarian cancer detection
This study is trying to see if the bacteria in the vagina can help detect ovarian cancer earlier by comparing samples from healthy women and those at higher risk or already diagnosed.
-
A network for advancing genomics research and improving health
This study is testing how sharing genetic information from patients can help doctors better understand diseases and improve treatments for everyone involved.
-
Molecular profiling and drug testing for pediatric acute myeloid leukemia
This study is trying to learn more about pediatric acute myeloid leukemia by looking at patients' cells to find out why some treatments don’t work and to test new drug options for kids and young adults with this cancer.
-
Futibatinib treatment for advanced cholangiocarcinoma with FGFR2 gene changes
This study is testing if two different doses of a new drug called futibatinib can help people with advanced bile duct cancer that has specific gene changes feel better after other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.